Vascodagama Online Journal

Lung Transplant Rejection Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Lung Transplant Rejection Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

March 21
05:56 2023
Lung Transplant Rejection Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Lung Transplant Rejection pipeline constitutes key companies continuously working towards developing Lung Transplant Rejection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Lung Transplant Rejection Overview

Lung transplantation (LTx) is the definitive surgical treatment for select progressive end-stage lung disease patients despite being on optimum medical therapy. However, more than 30% of the LTx patients experience complications including rejection of transplanted lung.

 

Lung Transplant Rejection Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lung Transplant Rejection Market.

 

The Lung Transplant Rejection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Lung Transplant Rejection Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Lung Transplant Rejection treatment therapies with a considerable amount of success over the years. Lung Transplant Rejection Key players such as – Corline Biomedical, MimeTech, TFF Pharmaceuticals, Kamada, Genentech, Bristol Myers Squibb, Bristol-Myers Squibb, Qx Therapeutics, TFF Pharma, and others, are developing therapies for the Lung Transplant Rejection treatment 
  • Lung Transplant Rejection Emerging therapies such as – Belatacept, QXT-101, TAC-LAC, and others are expected to have a significant impact on the Lung Transplant Rejection market in the coming years.   
  • Belatacept selectively blocks the process of T-cell activation. It is currently being investigated in Phase II clinical trials for patients with Lung Transplant Rejection by Bristol-Myers Squibb
  • TFF TAC-LAC is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine being investigated in the Phase I stage of development for the prevention of Rejection of Organ Transplant

 

Route of Administration

Lung Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Lung Transplant Rejection Pipeline Therapeutics Assessment

  • Lung Transplant Rejection Assessment by Product Type
  • Lung Transplant Rejection By Stage and Product Type
  • Lung Transplant Rejection Assessment by Route of Administration
  • Lung Transplant Rejection By Stage and Route of Administration
  • Lung Transplant Rejection Assessment by Molecule Type
  • Lung Transplant Rejection by Stage and Molecule Type

 

DelveInsight’s Lung Transplant Rejection Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Lung Transplant Rejection Drugs Under Different Phases of Clinical Development Include:

  • Belatacept: Bristol-Myers Squibb
  • QXT-101: Qx Therapeutics
  • TAC-LAC: TFF Pharma

 

Get a Free Sample PDF Report to know more about Lung Transplant Rejection Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/lung-transplant-rejection-pipeline-insight

 

Lung Transplant Rejection Pipeline Analysis:

The Lung Transplant Rejection pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Lung Transplant Rejection with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lung Transplant Rejection Treatment.
  • Lung Transplant Rejection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Lung Transplant Rejection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lung Transplant Rejection market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Lung Transplant Rejection product details are provided in the report. Download the Lung Transplant Rejection pipeline report to learn more about the emerging Lung Transplant Rejection therapies

 

Scope of Lung Transplant Rejection Pipeline Drug Insight    

  • Coverage: Global
  • Key Lung Transplant Rejection Companies: Bristol-Myers Squibb, Qx Therapeutics, TFF Pharma, and others
  • Key Lung Transplant Rejection Therapies: Belatacept, QXT-101, TAC-LAC, and others Lung Transplant Rejection Therapeutic Assessment: Lung Transplant Rejection current marketed and Lung Transplant Rejection emerging therapies
  • Lung Transplant Rejection Market Dynamics: Lung Transplant Rejection market drivers and Lung Transplant Rejection market barriers 

 

Request for Sample PDF Report for Lung Transplant Rejection Pipeline Assessment and clinical trials

 

Table of Contents

1

Lung Transplant Rejection Report Introduction

2

Lung Transplant Rejection Executive Summary

3

Lung Transplant Rejection Overview

4

Lung Transplant Rejection- Analytical Perspective In-depth Commercial Assessment

5

Lung Transplant Rejection Pipeline Therapeutics

6

Lung Transplant Rejection Late Stage Products (Phase II/III)

7

Lung Transplant Rejection Mid Stage Products (Phase II)

8

Lung Transplant Rejection Early Stage Products (Phase I)

9

Lung Transplant Rejection Preclinical Stage Products

10

Lung Transplant Rejection Therapeutics Assessment

11

Lung Transplant Rejection Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Lung Transplant Rejection Key Companies

14

Lung Transplant Rejection Key Products

15

Lung Transplant Rejection Unmet Needs

16 

Lung Transplant Rejection Market Drivers and Barriers

17

Lung Transplant Rejection Future Perspectives and Conclusion

18

Lung Transplant Rejection Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Lung Transplant Rejection drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories